trending Market Intelligence /marketintelligence/en/news-insights/trending/yjyixso3h7l4mo20c9t6dq2 content esgSubNav
In This List

Adaptimmune secures $100M funding from private equity firms


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Banking Essentials Newsletter: 7th February Edition

Case Study

A Bank Outsources Data Gathering to Meet Basel III Regulations

Adaptimmune secures $100M funding from private equity firms

Adaptimmune Therapeutics PLC said it had attracted a $100 million investment from a handful of private equity firms.

Adaptimmune entered an agreement with Matrix Capital Management Co. LP, New Enterprise Associates 16 LP, New Enterprise Associates 14 LP and Syncona Ltd. The firms will buy $100 million worth of the U.K.-based biopharmaceutical company's American depositary shares at $10 each.

The offering is expected to close Sept. 7, subject to customary closing conditions.

Adaptimmune said net proceeds will be used for the clinical development of its wholly owned pipeline of SPEAR T-cell candidates for treating multiple types of cancer and for other general corporate purposes.

In July, GlaxoSmithKline PLC acquired one of the cell therapy programs from Adaptimmune for about $27.5 million.

"This financing strengthens our balance sheet and extends our runway through to late 2020," Adaptimmune CEO James Noble said in a statement.